MXCT MAXCYTE, INC.
Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1287098 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-0.1%
TTM net income YoY38.7%
TTM EPS YoY39.5%
Revenue 3-yr CAGR-3.3%
Net income 3-yr CAGR—
Margins
Gross margin81.0%
Operating margin-98.0%
Net margin-81.4%
FCF margin-62.4%
EBITDA margin-86.5%
Returns
ROE-16.9%
ROA-14.1%
ROIC (approx.)-17.5%
Asset turnover0.17x
Leverage & solvency
Liabilities / assets17.3%
Debt / equity0.00x
Current ratio7.83x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-3.5%
Payout ratio—
Capex / revenue1.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $10.15M | $7.27M | $9.65M | $7.30M | $6.83M | $8.51M | $10.39M | $8.69M |
| Cost of revenue | $1.68M | $1.68M | $1.57M | $1.61M | $1.60M | $1.52M | $1.50M | $2.28M |
| Gross profit | $8.47M | $5.60M | $8.08M | $5.69M | $5.23M | $6.99M | $8.89M | $6.41M |
| R&D expense | $2.87M | $4.25M | $3.86M | $3.33M | $5.32M | $6.27M | $5.90M | $4.61M |
| SG&A expense | $6.55M | $7.26M | $5.97M | $5.48M | $6.03M | $8.08M | $8.53M | $7.21M |
| Operating income | -$6.04M | -$10.23M | -$6.18M | -$11.23M | -$14.15M | -$14.23M | -$12.29M | -$12.90M |
| Pretax income | -$4.76M | -$8.87M | -$4.75M | -$9.60M | -$12.42M | -$12.36M | -$10.26M | -$10.60M |
| Net income | -$4.76M | -$8.87M | -$4.75M | -$9.60M | -$12.42M | -$12.36M | -$10.26M | -$10.60M |
| EBITDA | -$5.17M | -$9.28M | -$5.14M | -$10.15M | -$13.11M | -$13.15M | -$11.20M | -$11.84M |
| EPS (basic) | -0.05 | -0.08 | -0.04 | — | -0.12 | -0.12 | -0.10 | — |
| EPS (diluted) | -0.05 | -0.08 | -0.04 | — | -0.12 | -0.12 | -0.10 | — |
| Weighted avg. shares (diluted) | 103.54M | 106.82M | 106.88M | — | 106.61M | 106.40M | 105.95M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $13.37M | $15.04M | $14.56M | $20.07M | $12.97M | $15.22M | $23.39M | $27.88M |
| Short-term investments | $87.91M | $90.65M | $92.30M | $82.98M | $92.75M | $111.34M | $114.89M | $126.60M |
| Receivables | $12.05M | $3.92M | $4.25M | $3.50M | $8.31M | $5.75M | $5.53M | $4.68M |
| Inventory | $7.38M | $7.80M | $7.63M | $7.55M | $7.61M | $7.93M | $8.27M | $8.91M |
| Current assets | $124.67M | $121.27M | $122.94M | $118.37M | $124.64M | $143.22M | $155.75M | $171.68M |
| PP&E, net | $14.34M | $14.90M | $16.64M | $17.53M | $18.62M | $19.40M | $19.92M | $19.71M |
| Goodwill | — | — | — | — | $3.55M | $3.75M | $3.92M | — |
| Intangibles | $749,000 | $766,000 | $783,000 | $650,000 | $667,000 | $638,000 | $650,000 | — |
| Total assets | $182.48M | $184.67M | $194.47M | $202.51M | $213.48M | $219.75M | $229.96M | $239.47M |
| Current liabilities | $15.92M | $9.89M | $10.21M | $14.27M | $16.10M | $11.55M | $12.73M | $15.78M |
| Total liabilities | $31.55M | $25.92M | $26.59M | $31.02M | $33.20M | $29.03M | $30.55M | $33.22M |
| Shareholders' equity | $150.93M | $158.75M | $167.89M | $171.49M | $180.28M | $190.72M | $199.41M | $206.25M |
| Shares outstanding | 103.23M | 106.13M | 107.12M | 106.79M | 106.64M | 106.59M | 106.31M | 105.71M |
| Cash flow statement | ||||||||
| Operating cash flow | -$5.51M | -$4.66M | -$8.17M | -$2.69M | -$7.46M | -$9.85M | -$14.41M | -$7.82M |
| Capital expenditure | $59,000 | $62,000 | $72,000 | $231,000 | $300,000 | $584,000 | $653,000 | $147,000 |
| Free cash flow | -$5.57M | -$4.72M | -$8.24M | -$2.92M | -$7.76M | -$10.44M | -$15.06M | -$7.97M |
| Investing cash flow | $7.86M | $6.57M | $2.66M | $9.68M | $5.19M | $1.54M | $9.53M | -$1.67M |
| Financing cash flow | -$4.02M | -$1.42M | $5,000 | $105,000 | $14,000 | $154,000 | $383,000 | $412,000 |
| Depreciation & amortization | $868,000 | $953,000 | $1.05M | $1.07M | $1.04M | $1.08M | $1.10M | $1.06M |
| Stock-based compensation | $963,000 | $1.16M | $1.14M | $706,000 | $1.95M | $3.51M | $3.04M | $3.13M |
| Share buybacks | $4.02M | — | — | — | — | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.